Literature DB >> 10733581

Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1.

C Missero1, M T Pirro, R Di Lauro.   

Abstract

Expression of oncogenic Ras in thyroid cells results in loss of expression of several thyroid-specific genes and inactivation of TTF-1, a homeodomain-containing transcription factor required for normal development of the thyroid gland. In an effort to understand how signal transduction pathways downstream of Ras may be involved in suppression of the differentiated phenotype, we have tested mutants of the Ras effector region for their ability to affect TTF-1 transcriptional activity in a transient-transfection assay. We find that V12S35 Ras, a mutant known to interact specifically with Raf but not with RalGDS or phosphatidylinositol 3-kinase (PI3 kinase) inhibits TTF-1 activity. Expression of an activated form of Raf (Raf-BXB) also inhibits TTF-1 function to a similar extent, while the MEK inhibitors U0126 and PD98059 partially relieve Ras-mediated inactivation of TTF-1, suggesting that the extracellular signal-regulated kinase (ERK) pathway is involved in this process. Indeed, ERK directly phosphorylates TTF-1 at three serine residues, and concomitant mutation of these serines to alanines completely abolishes ERK-mediated phosphorylation both in vitro and in vivo. Since activation of the Raf/MEK/ERK pathway accounts for only part of the activity elicited by oncogenic Ras on TTF-1, other downstream pathways are likely to be involved in this process. We find that activation of PI3 kinase, Rho, Rac, and RalGDS has no effect on TTF-1 transcriptional activity. However, a poorly characterized Ras mutant, V12N38 Ras, can partially repress TTF-1 transcriptional activity through an ERK-independent pathway. Importantly, concomitant expression of constitutive activated Raf and V12N38 Ras results in almost complete loss of TTF-1 activity. Our data indicate that the Raf/MEK/ERK cascade may act in concert with an as-yet-uncharacterized signaling pathway activated by V12N38 Ras to repress TTF-1 function and ultimately to inhibit thyroid cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733581      PMCID: PMC85494          DOI: 10.1128/MCB.20.8.2783-2793.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  65 in total

1.  The homeodomain transcription factor NK-4 acts as either a transcriptional activator or repressor and interacts with the p300 coactivator and the Groucho corepressor.

Authors:  C Y Choi; Y M Lee; Y H Kim; T Park; B H Jeon; R A Schulz; Y Kim
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

Review 2.  Control of the ERK MAP kinase cascade by Ras and Raf.

Authors:  R Marais; C J Marshall
Journal:  Cancer Surv       Date:  1996

3.  One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes.

Authors:  A Fusco; M T Berlingieri; P P Di Fiore; G Portella; M Grieco; G Vecchio
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

4.  Culture of hormone-dependent functional epithelial cells from rat thyroids.

Authors:  F S Ambesi-Impiombato; L A Parks; H G Coon
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

5.  Phosphatidylinositol-3-OH kinase as a direct target of Ras.

Authors:  P Rodriguez-Viciana; P H Warne; R Dhand; B Vanhaesebroeck; I Gout; M J Fry; M D Waterfield; J Downward
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

6.  Mutations that abolish the ability of Ha-Ras to associate with Raf-1.

Authors:  M Shirouzu; H Koide; J Fujita-Yoshigaki; H Oshio; Y Toyama; K Yamasaki; S A Fuhrman; E Villafranca; Y Kaziro; S Yokoyama
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

7.  Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.

Authors:  F Hofer; S Fields; C Schneider; G S Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

Review 8.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways.

Authors:  A J Whitmarsh; R J Davis
Journal:  J Mol Med (Berl)       Date:  1996-10       Impact factor: 4.599

9.  Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK.

Authors:  A Minden; A Lin; M McMahon; C Lange-Carter; B Dérijard; R J Davis; G L Johnson; M Karin
Journal:  Science       Date:  1994-12-09       Impact factor: 47.728

10.  ralGDS family members interact with the effector loop of ras p21.

Authors:  A Kikuchi; S D Demo; Z H Ye; Y W Chen; L T Williams
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

View more
  20 in total

1.  Two distinct E3 ligases, SCFFBXL19 and HECW1, degrade thyroid transcription factor 1 in normal thyroid epithelial and follicular thyroid carcinoma cells, respectively.

Authors:  Jia Liu; Su Dong; Heather Wang; Lian Li; Qinmao Ye; Yanhui Li; Jiaxing Miao; Sissy Jhiang; Jing Zhao; Yutong Zhao
Journal:  FASEB J       Date:  2019-06-25       Impact factor: 5.191

2.  Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription.

Authors:  Laura Casalino; Latifa Bakiri; Francesco Talotta; Jonathan B Weitzman; Alfredo Fusco; Moshe Yaniv; Pasquale Verde
Journal:  EMBO J       Date:  2007-03-08       Impact factor: 11.598

3.  The E3 ubiquitin ligase HECW1 targets thyroid transcription factor 1 (TTF1/NKX2.1) for its degradation in the ubiquitin-proteasome system.

Authors:  Jia Liu; Su Dong; Lian Li; Heather Wang; Jing Zhao; Yutong Zhao
Journal:  Cell Signal       Date:  2019-03-05       Impact factor: 4.315

4.  Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Authors:  James Nagarajah; Mina Le; Jeffrey A Knauf; Giuseppe Ferrandino; Cristina Montero-Conde; Nagavarakishore Pillarsetty; Alexander Bolaender; Christopher Irwin; Gnana Prakasam Krishnamoorthy; Mahesh Saqcena; Steven M Larson; Alan L Ho; Venkatraman Seshan; Nobuya Ishii; Nancy Carrasco; Neal Rosen; Wolfgang A Weber; James A Fagin
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

5.  Oncogenic ras blocks the cAMP pathway and dedifferentiates thyroid cells via an impairment of pax8 transcriptional activity.

Authors:  Maria Giuseppina Baratta; Immacolata Porreca; Roberto Di Lauro
Journal:  Mol Endocrinol       Date:  2009-03-12

6.  [EGFR mutation analysis in non-small-cell lung cancer : Experience from routine diagnostics].

Authors:  C Tapia; S Savic; M Bihl; A Rufle; I Zlobec; L Terracciano; L Bubendorf
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

7.  Gene expression profile of epithelial-mesenchymal transition mediators in papillary thyroid cancer.

Authors:  Ana Lopez-Campistrous; Esther Ekpe Adewuyi; David C Williams; Todd P W McMullen
Journal:  Endocrine       Date:  2020-09-10       Impact factor: 3.633

8.  Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization.

Authors:  Laura Casalino; Dario De Cesare; Pasquale Verde
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

9.  Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Authors:  Brian R Untch; Vanessa Dos Anjos; Maria E R Garcia-Rendueles; Jeffrey A Knauf; Gnana P Krishnamoorthy; Mahesh Saqcena; Umeshkumar K Bhanot; Nicholas D Socci; Alan L Ho; Ronald Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2018-05-14       Impact factor: 12.701

10.  Maximization of negative correlations in time-course gene expression data for enhancing understanding of molecular pathways.

Authors:  Tao Zeng; Jinyan Li
Journal:  Nucleic Acids Res       Date:  2009-10-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.